Literature DB >> 12507832

In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa.

W Song1, H J Woo, J S Kim, K M Lee.   

Abstract

Using the chequerboard titration method, the activity in combination of beta-lactams, fluoroquinolones and aminoglycosides was investigated against 24 Pseudomonas aeruginosa isolates resistant to these antibiotics. Synergy was detected with one or more antimicrobial combinations against 15 of 24 (63%) isolates and partial synergy was detected with one or more combinations against all 24 isolates. No antagonism was seen with any combination. Ceftazidime and cefepime with aztreonam, amikacin and isepamicin showed synergy or partial synergy against 12-20 (50-80%) isolates. Imipenem and meropenem with amikacin and isepamicin showed synergy or partial synergy against eight to 12 (33-50%) isolates. The results of this study indicate that against P. aeruginosa, synergy may occur between beta-lactams, fluoroquinolones and aminoglycosides although the strains are resistant to the individual antibiotics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507832     DOI: 10.1016/s0924-8579(02)00269-8

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Determination of minimal regrowth concentration (MRC) in clinical isolates of various biofilm-forming bacteria.

Authors:  L Cernohorská; M Votava
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

2.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  Antibiotic synergy against biofilm-forming Pseudomonas aeruginosa.

Authors:  L Cernohorská; M Votava
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.099

4.  Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.

Authors:  Vincent H Tam; Amy N Schilling; Russell E Lewis; David A Melnick; Adam N Boucher
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.

Authors:  Duangchit Panomvana; Sam-Ang Kiatjaroensin; Danabhand Phiboonbanakit
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients.

Authors:  K E N Milne; I M Gould
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

7.  Rate of isolation and trends of antimicrobial resistance of multidrug resistant pseudomonas aeruginosa from otorrhea in chronic suppurative otitis media.

Authors:  Sun Kyu Lee; Dong Choon Park; Myung Gu Kim; Sung Hyun Boo; Young Joon Choi; Jae Yong Byun; Moon Suh Park; Seung Geun Yeo
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-03-22       Impact factor: 3.372

8.  Interactions of antibiotics and methanolic crude extracts of Afzelia Africana (Smith.) against drug resistance bacterial isolates.

Authors:  Olayinka Aiyegoro; Adekanmi Adewusi; Sunday Oyedemi; David Akinpelu; Anthony Okoh
Journal:  Int J Mol Sci       Date:  2011-07-13       Impact factor: 5.923

9.  Toxin A and B genes expression of Clostridium difficile in the sub-minimum inhibitory concentration of clindamycin, vancomycin and in combination with ceftazidime.

Authors:  Mohammad Moradi; Shahla Mansouri; Nouzar Nakhaee; Farhad Sarafzadeh; Ebrahim Rezazadeh Zarandi
Journal:  Iran J Microbiol       Date:  2020-02

10.  In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.

Authors:  Devrim Dundar; Metin Otkun
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.